Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Eastern Cooperative Oncology Group

Status and phase

Completed

Phase 3

Conditions

Breast Cancer

Treatments

Drug: bevacizumab

Drug: Paclitaxel

Study type

Interventional

Funder types

NETWORK

NIH

Identifiers

NCT00028990

NCCTG-E2100

NSABP-E2100

CAN-NCIC-MAC3

CDR0000069156

E2100

Details and patient eligibility

About

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. It is not yet known whether paclitaxel works better with or without bevacizumab in treating breast cancer.

PURPOSE: This randomized phase III trial is to see if paclitaxel works better with or without bevacizumab in treating patients who have locally recurrent or metastatic breast cancer.

Full description

OBJECTIVES:

Compare the time to treatment failure in patients with locally recurrent or metastatic breast cancer treated with paclitaxel with or without bevacizumab.
Compare the objective response rate, duration of response, overall survival, and time to progression in patients treated with these regimens.
Compare the toxicity of these regimens in these patients.
Compare the quality of life of patients treated with these regimens.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to disease-free interval (no more than 24 months vs more than 24 months), number of metastatic sites (less than 3 vs 3 or more), treatment with prior adjuvant chemotherapy (yes vs no), and estrogen receptor status (positive vs negative vs unknown). Patients are randomized to one of two treatment arms.

Arm I: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 followed by bevacizumab IV over 30-90 minutes on days 1 and 15.
Arm II: Patients receive paclitaxel as in arm I. In both arms, courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline and on day 1 of weeks 17 and 33.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 316-650 patients (158-325 per treatment arm) will be accrued for this study within 31 months.

Enrollment

722 patients

Sex

All

Ages

18 to 120 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

Histologically or cytologically confirmed adenocarcinoma of the breast
Locally recurrent disease that is not amenable to surgical resection with curative intent OR
Metastatic disease
No HER-2-overexpressing (3+) breast cancer unless previously treated with trastuzumab (Herceptin)
- Unknown HER-2 status allowed provided herceptin-based therapy inappropriate or not indicated
No prior or radiologic evidence of CNS metastases, including previously treated, resected, or asymptomatic brain lesions or leptomeningeal involvement by head CT scan or MRI
Hormone receptor status:
- Not specified

PATIENT CHARACTERISTICS:

Age:

18 and over

Sex:

Male or female

Menopausal status:

Not specified

Performance status:

ECOG 0-1

Life expectancy:

Not specified

Hematopoietic:

Absolute neutrophil count at least 1,500/mm^3
Platelet count at least 100,000/mm^3
No prior bleeding diathesis

Hepatic:

Bilirubin no greater than 1.5 mg/dL
SGOT no greater than 2 times upper limit of normal (ULN) (5 times ULN for known liver involvement)
PT/PTT no greater than 1.5 times normal
INR no greater than 1.5 times normal

Renal:

Creatinine no greater than 2.0 mg/dL
No proteinuria by dipstick urinalysis
Trace proteinuria allowed
Proteinuria less than 500 mg by 24-hour urine collection if proteinuria at least 1+ by urinalysis

Cardiovascular:

No clinically significant cardiovascular disease
No myocardial infarction within the past 12 months
No unstable angina
No prior deep vein thrombosis
No grade 2 or greater peripheral vascular disease
No uncontrolled congestive heart failure
No uncontrolled hypertension (systolic blood pressure greater than 170 mmHg and diastolic blood pressure greater than 95 mm Hg)
No prior cerebrovascular accident

Pulmonary:

No prior pulmonary embolism

Other:

Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective non-hormonal contraception
No history of seizures
No non-healing wound or fracture
No hypersensitivity to paclitaxel, Cremophor EL, Chinese hamster ovary cell products, or other recombinant human antibodies
No active infection requiring parenteral antibiotics

PRIOR CONCURRENT THERAPY:

Biologic therapy:

See Disease Characteristics

Chemotherapy:

No prior chemotherapy for locally recurrent or metastatic breast cancer
At least 12 months since prior adjuvant or neoadjuvant taxane therapy
At least 3 weeks since prior adjuvant chemotherapy

Endocrine therapy:

At least 3 weeks since prior hormonal therapy for locally recurrent or metastatic breast cancer

Radiotherapy:

At least 3 weeks since prior radiotherapy
No prior radiotherapy to only site of disease
No concurrent local radiotherapy for pain control or life-threatening situations (e.g, superior vena cava syndrome, spinal cord compression, or CNS metastases)

Surgery:

At least 4 weeks since prior major surgical procedure except placement of vascular access device or breast biopsy
At least 7 days since prior minor surgical procedure, including placement of an access device or fine needle aspiration

Other:

At least 10 days since prior anticoagulant therapy (low-dose anticoagulant therapy to maintain patency of a vascular access device allowed)
At least 10 days since prior and no concurrent daily aspirin (more than 325 mg/day) or other non-steroidal anti-inflammatory medication known to inhibit platelet function
No concurrent dipyridamole, ticlopidine, clopidogrel, or cilostazol